Pavmed Inc SEC Filings

PAVMZ NASDAQ

Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVMZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Monitoring a medical-technology firm that juggles esophageal-cancer diagnostics, implantable sensors and multiple financing vehicles isn’t easy. PAVmed’s filings often bundle FDA milestones, warrant conversions and subsidiary updates into dense exhibits. If you’ve ever searched “PAVmed SEC filings explained simply” or wondered why an 8-K mentions EsoGuard trial data, Stock Titan’s AI-powered summaries turn that tangle into clear, actionable notes within seconds.

Every document—from a PAVmed quarterly earnings report 10-Q filing to a sudden 8-K describing Collect+Protect validation—is captured the moment it hits EDGAR. Our platform tags PAVmed insider trading Form 4 transactions and pushes PAVmed Form 4 insider transactions real-time to your dashboard. Need a deeper dive? The engine links each metric in the PAVmed earnings report filing analysis to prior periods, flags liquidity changes in a PAVmed annual report 10-K simplified view, and even highlights pay packages tucked inside a PAVmed proxy statement executive compensation section.

Whether you’re assessing reimbursement risk, tracking PAVmed executive stock transactions Form 4 before capital raises, or simply understanding PAVmed SEC documents with AI, you’ll find the data in context: segment revenue for Lucid Diagnostics, Veris Health burn rates, and 510(k) updates all mapped to historical trends. No spreadsheets to build—just reliable intelligence on PAVmed 8-K material events explained and updated in real time.

06/24/2025 08:15 AM

Filing

[8-K] PAVmed Inc. Series Z Warrant Reports Material Event

Rhea-AI Summary

Roblox Corporation (RBLX) – Form 144 filing dated June 25, 2025

The notice discloses the intent to sell 9,586 Class A common shares through Morgan Stanley Smith Barney on or after 06/25/2025, with an estimated market value of $1,004,421.08. The filing lists David Brent Baszucki and related entities (family foundation, gift trusts) as recent sellers.

Recent insider activity (past three months)

44 separate sales transactions from 04/07/2025 – 06/24/2025.
Approximate aggregate volume: ~7.7 million shares, equal to roughly 1.2 % of the 629,990,658 shares outstanding.
Largest single-day sale: 1,375,002 shares on 05/05/2025 under a Rule 10b5-1 plan, generating proceeds of about $99.3 million.
Total disclosed gross proceeds for the period exceed $600 million (sum of table values).

The filer represents that no undisclosed material adverse information is known and indicates reliance on Rule 10b5-1 trading plans for several transactions.

Key take-aways for investors

The CEO and affiliated parties have disposed of a significant number of shares in a short period, continuing with a new 9,586-share sale.
Although sales are under pre-arranged 10b5-1 plans, sustained insider selling can signal reduced insider exposure and may add share-supply pressure.
No operational or financial performance metrics are included in Form 144; the filing serves solely as notice of proposed sales.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Pavmed (PAVMZ)?

The current stock price of Pavmed (PAVMZ) is $0.0009 as of April 30, 2025.

What are the main business segments of PAVmed Inc?

PAVmed operates across three main segments: diagnostics, medical devices, and digital health. Each segment is designed to address unmet clinical needs, with a particular focus on early detection and prevention.

How does PAVmed accelerate product commercialization?

PAVmed employs a business model focused on capital and time efficiency, leveraging advanced technologies and entrepreneurial expertise to rapidly bring innovative products from concept to market.

What innovation differentiates PAVmed from legacy medical device companies?

PAVmed differentiates itself by integrating proprietary technologies, such as Collect+Protect™ in its EsoCheck device, which offers targeted and noninvasive cell collection with enhanced diagnostics accuracy.

Can you explain the role of its subsidiaries in its overall strategy?

PAVmed’s subsidiaries, like Lucid Diagnostics and Veris Health, specialize in cancer prevention diagnostics and personalized digital health solutions. This structure allows each unit to focus on operational excellence and achieve independent financing.

How does the company ensure the quality of its diagnostic solutions?

Quality is maintained through rigorous clinical testing and validation. PAVmed’s products are supported by substantial clinical evidence, ensuring that diagnostic results are both sensitive and specific to disease detection.

What market need is PAVmed addressing with its products?

PAVmed addresses the critical need for early detection of esophageal precancer and cancer. Its noninvasive tests offer a safer, more efficient alternative to traditional invasive methods, thereby improving patient outcomes.

How does the digital health component contribute to patient care?

The digital health platform, developed through its Veris Health subsidiary, enhances personalized cancer care by integrating remote monitoring, real-time symptom reporting, and data-driven insights into patient management.

What are the key benefits for healthcare providers using PAVmed's technologies?

Healthcare providers benefit from improved diagnostic accuracy, faster turnaround times, and access to advanced data analytics. This supports more efficient patient triage and cost-effective care delivery, ultimately enhancing patient safety.